文献速递神经肿瘤

接触孕激素类药物患者的脑膜瘤:一项真实世界筛查项目的结果

Meningioma in patients exposed to progestin drugs: results from a real-life screening program.
PubMed 文献 · J Neurooncol · 2022-09-06

法国当局对接触孕激素治疗(醋酸环丙孕酮、醋酸诺美孕酮、醋酸氯地孕酮)的患者实施系统性脑膜瘤筛查,本前瞻性单中心研究纳入210例患者,15例(7.1%)发现至少一个脑膜瘤,其中7例(47%)为多发;CPA暴露组脑膜瘤发生率高于NA和CMA组,停药后多数患者肿瘤负荷下降。

要点

  • CPA暴露组脑膜瘤发生率13%(13/103),高于NA组4%(1/22)和CMA组1%(1/85),P=0.005。
  • CPA暴露者中,脑膜瘤与更长治疗时间(中位20年 vs 7年,P=0.001)和更高累积剂量(中位91g vs 62g,P=0.014)相关。
  • 14例停药患者中11例(79%)脑膜瘤负荷下降,MRI随访期间无进展病例。

核心结论

  • 系统性MRI筛查可发现孕激素暴露患者的小型、多发脑膜瘤,这些肿瘤可保守管理,停药后体积缩小。
  • CPA暴露后脑膜瘤高发率强化了系统筛查的必要性。
  • 对于NA和CMA,需要进一步研究以确定最可能从筛查中获益的患者。

研究设计与样本

  • 前瞻性单中心研究,纳入2018年9月至2021年4月期间接受标准化MRI(钆增强、轴位T2 FLAIR和3D-T1梯度回波序列)进行脑膜瘤筛查的患者,共210例。

主要发现

  • 210例患者中15例(7.1%)至少有一个脑膜瘤,其中7例(7/15,47%)为多发脑膜瘤。
  • 脑膜瘤在老年患者中更常见,CPA暴露组为13/103(13%),NA组为1/22(4%),CMA组为1/85(1%),P=0.005。
  • CPA暴露后,脑膜瘤与更长治疗时间(中位20年 vs 7年,P=0.001)和更高累积剂量(中位91g vs 62g,P=0.014)相关。
  • 脑膜瘤多发与更高CPA剂量相关(中位244g vs 61g,P=0.027)。
  • 大多数脑膜瘤≤1 cm³(44/58,76%),且为凸面脑膜瘤(36/58,62%)。

临床怎么用

  • 原文结论指出,对孕激素暴露患者进行系统性MRI筛查可发现小型、多发脑膜瘤,这些肿瘤可保守管理,停药后缩小。
  • 原文结论认为CPA暴露后脑膜瘤高发率强化了系统筛查的必要性;对于NA和CMA,原文认为需要进一步研究以确定最可能从筛查中获益的患者。

局限性

  • 原文结论指出,对于NA和CMA,需要进一步研究以确定最可能从筛查中获益的患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To report the results of systematic meningioma screening program implemented by French authorities in patients exposed to progestin therapies (cyproterone (CPA), nomegestrol (NA), and chlormadinone (CMA) acetate). METHODS: We conducted a prospective monocentric study on patients who, between September 2018 and April 2021, underwent standardized MRI (injection of gadolinium, then a T2 axial FLAIR and a 3D-T1 gradient-echo sequence) for meningioma screening. RESULTS: Of the 210 included patients, 15 (7.1%) had at least one meningioma; seven (7/15, 47%) had multiple meningiomas. Meningiomas were more frequent in older patients and after exposure to CPA (13/103, 13%) compared to NA (1/22, 4%) or CMA (1/85, 1%; P = 0.005). After CPA exposure, meningiomas were associated with longer treatment duration (median = 20 vs 7 years, P = 0.001) and higher cumulative dose (median = 91 g vs. 62 g, P = 0.014). Similarly, their multiplicity was associated with higher dose of CPA (median = 244 g vs 61 g, P = 0.027). Most meningiomas were ≤ 1 cm3 (44/58, 76%) and were convexity meningiomas (36/58, 62%). At diagnosis, patients were non-symptomatic, and all were managed conservatively. Among 14 patients with meningioma who stopped progestin exposure, meningioma burden decreased in 11 (79%) cases with no case of progression during MR follow-up. CONCLUSION: Systematic MR screening in progestin-exposed patients uncovers small and multiple meningiomas, which can be managed conservatively, decreasing in size after progestin discontinuation. The high rate of meningiomas after CPA exposure reinforces the need for systematic screening. For NA and CMA, further studies are needed to identify patients most likely to benefit from screening.

来源:J Neurooncol,查看原文。版权归原作者所有。

引用

  1. Samoyeau T, Provost C, Roux A, et al. Meningioma in patients exposed to progestin drugs: results from a real-life screening program. J Neurooncol. 2022. PMID: 36066786. doi:10.1007/s11060-022-04124-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。